Lung Non-Squamous Non-Small Cell Carcinoma Recruiting Phase 3 Trials for Pembrolizumab (DB09037)

IndicationStatusPhase
DBCOND0116675 (Lung Non-Squamous Non-Small Cell Carcinoma)Recruiting3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03793179Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung CancerTreatment